Bissan Al-Lazikani

List of Publications by Year
in descending order

58	10,964	236833	223716
papers	citations	25 h-index	46 g-index

62	62	62	18203
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. Cancer Research, 2022, 81, 1087-1100.	0.4	23
2	PDBe-KB: collaboratively defining the biological context of structural data. Nucleic Acids Research, 2022, 50, D534-D542.	6.5	46
3	Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21.	1.7	39
4	Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligenceâ€“Enabled Studies of Acute Phosphoproteomic Changes. Molecular Cancer Therapeutics, 2022, 21, 1020-1029.	1.9	3
5	canSAR chemistry registration and standardization pipeline. Journal of Cheminformatics, 2022, 14, .	2.8	5
6	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2021, 49, D1074-D1082.	6.5	63
7	Tuning Local Hydration Enables a Deeper Understanding of Proteinâ€“Ligand Binding: The PP1-Src Kinase Case. Journal of Physical Chemistry Letters, 2021, 12, 49-58.	2.1	5
8	Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry, 2021, 13, 731-747.	1.1	24
9	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	2.5	13
10	PDBe-KB: a community-driven resource for structural and functional annotations. Nucleic Acids Research, 2020, 48, D344-D353.	6.5	87
11	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports, 2020, 10, 16000.	1.6	8
12	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	1.6	68
13	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38, 5905-5920.	2.6	23
14	Transforming cancer drug discovery with Big Data and AI. Expert Opinion on Drug Discovery, 2019, 14, 1089-1095.	2.5	22
15	Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. Molecular Cancer Therapeutics, 2019, 18, 1396-1404.	1.9	14
16	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2019, 47, D917-D922.	6.5	75
17	Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors. , 2019, , .		0
18	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182

#	Article	IF	Citations
19	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology, 2018, 25, 194-205.e5.	2.5	71
20	Leveraging Human Genetics to Guide Cancer Drug Development. JCO Clinical Cancer Informatics, 2018, 2, 1-11.	1.0	3
21	Unravelling the context specificity of signalling in KRAS mutant cancers: Implications for design of clinical trials. Annals of Oncology, 2018, 29, iii7.	0.6	3
22	Genomics, bio specimens, and other biological data: Current status and future directions. Medical Physics, 2018, 45, e829-e833.	1.6	3
23	Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation. , 2018, , .		0
24	Abstract B096: canSAR, a cancer research and drug discovery knowledgebase. Molecular Cancer Therapeutics, 2018, 17, B096-B096.	1.9	1
25	Abstract 776: Utilising genetic susceptibility and big data to inform novel cancer therapies. , 2018, , .		0
26	Abstract 1821: Genome-wide genetic screens define the drug resistance landscape of BRAF mutant colon cancer. , 2018, , .		0
27	Abstract A067: Targeting the bromodomain and extra-terminal (BET) family proteins and beyond in metastatic castration-resistant prostate cancer (mCRPC): Overcoming aberrant androgen receptor (AR) signaling. , 2018, , .		0
28	Rational design of non-resistant targeted cancer therapies. Scientific Reports, 2017, 7, 46632.	1.6	11
29	A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery, 2017, 16, 19-34.	21.5	1,608
30	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design, 2017, 22, 6935-6945.	0.9	65
31	SiGNet: A signaling network data simulator to enable signaling network inference. PLoS ONE, 2017, 12, e0177701.	1.1	7
32	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. ELife, 2017, 6, .	2.8	32
33	Abstract 996: A translational phosphoproteomic approach to study differences inKRASsignaling in pancreatic, colorectal and lung cancers. , 2017, , .		0
34	Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome. Future Medicinal Chemistry, 2016, 8, 1711-1716.	1.1	4
35	Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718.	21.5	111
36	canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2016, 44, D938-D943.	6.5	114

#	Article	IF	Citations
37	Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, 2016, 7, 3658-3661.	0.8	11
38	Abstract 4383: SOCRATES: integrating ex vivo and in silico analysis to identify optimal drug combinations for patients. , 2016, , .		0
39	Abstract 3099:KRASand clinical context: Differential dynamic signaling output ofKRASmutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs. , 2016, , .		0
40	Distinctive Behaviors of Druggable Proteins in Cellular Networks. PLoS Computational Biology, 2015, 11, e1004597.	1.5	43
41	Therapeutic opportunities within the DNA damage response. Nature Reviews Cancer, 2015, 15, 166-180.	12.8	442
42	canSAR: updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2014, 42, D1040-D1047.	6.5	69
43	Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition. , 2014, , .		1
44	Abstract 4164: The druggable proteome: Identifying novel target families for cancer. , 2014, , .		0
45	Drugging cancer genomes. Nature Reviews Drug Discovery, 2013, 12, 889-890.	21.5	47
46	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	21.5	111
47	A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European Journal of Cancer, 2013, 49, 2512-2521.	1.3	11
48	Unpicking the Combination Lock for Mutant BRAF and RAS Melanomas. Cancer Discovery, 2013, 3, 14-19.	7.7	8
49	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Current Opinion in Pharmacology, 2013, 13, 486-496.	1.7	55
50	canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Research, 2012, 40, D947-D956.	6.5	62
51	Shouldn't enantiomeric purity be included in the 'minimum information about a bioactive entity? Response from the MIABE group. Nature Reviews Drug Discovery, 2012, 11, 730-730.	21.5	0
52	ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Research, 2012, 40, D1100-D1107.	6.5	3,028
53	Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692.	9.4	883
54	Personalized Medicine: Patient-Predictive Panel Power. Cancer Cell, 2012, 21, 455-458.	7.7	16

#	Article	IF	Citations
55	Minimum information about a bioactive entity (MIABE). Nature Reviews Drug Discovery, 2011, 10, 661-669.	21.5	80
56	Genomic-scale prioritization of drug targets: the TDR Targets database. Nature Reviews Drug Discovery, 2008, 7, 900-907.	21.5	282
57	How many drug targets are there?. Nature Reviews Drug Discovery, 2006, 5, 993-996.	21.5	3,073
58	The Molecular Basis of Predicting Druggability. , 0, , 1315-1334.		5